News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
First launches expected in H1 2022
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
This is the company’s first partnership arrangement in China
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
